Investors

The Future of EarlyCDT^®

EarlyCDT^® uses patented technology to detect cancer in its early stages when the possibility of a cure is highest. No other methodology currently offers this kind of “power to know.”Oncimmune^®’s first product—EarlyCDT^®-Lung—will soon be followed by tests for solid-tumor cancers such as those of the breast, colon, prostate, stomach, pancreas and ovaries. This ongoing research and production provides a strong investment opportunity with excellent prospects for future growth.Over the past 5 years £23m ($35m) has been invested by Nottingham University, Balderton Capital Management which is one of the largest venture capital funds in Europe, senior employees and a number of private individuals, in developing the product and its associated technology.